key: cord-1034751-kidfxbz9
authors: Koning, Rutger; Bastard, Paul; Casanova, Jean-Laurent; Brouwer, Matthijs C.; van de Beek, Diederik
title: Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients
date: 2021-04-09
journal: Intensive Care Med
DOI: 10.1007/s00134-021-06392-4
sha: 0176abcc167733d9134096f85164fa342b6f76af
doc_id: 1034751
cord_uid: kidfxbz9

nan

unit (ICU) patients were included who were admitted for other reasons than respiratory viral illness including COVID-19 (Supplemental Information). Clinical data were collected prospectively and blood samples were tested for auto-Abs against IFN-α2 and IFN-ω with a multiplex particle-based assay and ELISA. Blocking activity of auto-Abs was measured with a STAT1 phosphorylation assay.

Auto-Abs against IFN-I were found in 35 of 210 (17%) COVID-19 patients of whom 6 of 35 (17%) had neutralizing auto-Abs (Table 1) . Neutralizing auto-Abs were only found in patients with severe COVID-19, all of whom required ICU admission compared to 83 of 204 (41%) of patients without neutralizing auto-Abs (p = 0.005). Disease course was complicated by thromboembolic events in 3 of 6 patients (50%), acute kidney injury in 4 of 6 patients (67%) and superinfections in 4 of 6 patients (67%). Five of 6 patients (83%) died compared to 52 of 204 (26%) patients without neutralizing auto-Abs (p = 0.006) including 35 of 83 (42%) in the ICU (p = 0.086). All five patients with neutralizing auto-Abs died of COVID-19-induced multi-organ failure.

Auto-Abs without neutralizing ability in vitro were detected in 26 of 210 COVID-19 patients (12%). Presence of these auto-Abs had no effect on clinical course (Table 1; Supplementary Table 3) . Auto-abs without neutralizing ability were present in 6 of 37 (16%) non-COVID-19 patients. The proportion of ICU patients with these auto-Abs was similar between COVID-19 and non-COVID-19 (12 of 89 [13%] vs. 6 of 37 [16%]; p = 0.78).

Our study shows that auto-Abs against IFN-I that are not neutralizing in vitro occur frequently in ICU patients (16%), irrespective of COVID-19 infection. Auto-Abs that neutralize IFN-I were only found in severe COVID-19 patients and are associated with mortality. The cause of death was COVID-19-induced multi-organ failure in all, presumably attributed in part to inadequate IFN-I responses [3] . The antiviral immune response might be improved by therapies targeting neutralizing auto-Abs. As patients with non-neutralizing auto-Abs are not expected to benefit from such therapy, adequate patient selection is vital for future trials exploring auto-Abs targeted treatment. 

All participants provided written informed consent, if applicable.

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by-nc/4. 0/.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Autoantibodies against cytokines: phenocopies of primary immunodeficiencies?

Life-threatening COVID-19: defective interferons unleash excessive inflammation